Tawa A, Kawa K, Shu K, Ikeda T, Yabuuchi H, Okada A
Gan To Kagaku Ryoho. 1982 May;9(5):849-54.
Seven children with advanced neuroblastoma were treated with maturation therapy. This therapy consisted of 12 hours drip infusion of papaverine (40-45 mg/kg/day) for 2 days with or without high dose cyclophosphamide (2,000-3,600 mg/m2). During maturation therapy all patients received intravenous hyperalimentation. One patient who had received papaverine alone did not respond to the therapy. Among 6 patients treated with papaverine and high dose cyclophosphamide, 3 responded to the therapy, 2 did not and one died soon after the therapy. However, similar responses were obtained in 2 of 3 responders with high dose cyclophosphamide alone. After all, papaverine infusion was evaluated to be effective only in one patient. The clinically severe complications of papaverine infusion were somnolence in all patients and extrapyramidal symptoms in 6 patients. Because of these extremely high toxicity rates with little evidence of therapeutic effect, selection for this therapy should be carefully done and the treatment plan should be reconsidered.
七名患有晚期神经母细胞瘤的儿童接受了成熟疗法。该疗法包括持续12小时静脉滴注罂粟碱(40 - 45毫克/千克/天),持续2天,同时可联合或不联合高剂量环磷酰胺(2000 - 3600毫克/平方米)。在成熟疗法期间,所有患者均接受静脉高营养支持。一名仅接受罂粟碱治疗的患者对该疗法无反应。在6名接受罂粟碱和高剂量环磷酰胺治疗的患者中,3名对治疗有反应,2名无反应,1名在治疗后不久死亡。然而,在3名有反应的患者中,有2名仅使用高剂量环磷酰胺也获得了类似的反应。毕竟,罂粟碱输注仅在1名患者中被评估为有效。罂粟碱输注的临床严重并发症包括所有患者均出现嗜睡,6名患者出现锥体外系症状。由于这些极高的毒性发生率且几乎没有治疗效果的证据,应谨慎选择该疗法,并重新考虑治疗方案。